Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTOZDWXX)

DOT Name Transmembrane protein 176A (TMEM176A)
Synonyms Hepatocellular carcinoma-associated antigen 112
Gene Name TMEM176A
Related Disease
Adult lymphoma ( )
Advanced cancer ( )
Carcinoma of esophagus ( )
Carcinoma of liver and intrahepatic biliary tract ( )
Colorectal carcinoma ( )
Esophageal cancer ( )
Esophageal squamous cell carcinoma ( )
Liver cancer ( )
Lung carcinoma ( )
Lymphoma ( )
Metastatic malignant neoplasm ( )
Neoplasm ( )
Neoplasm of esophagus ( )
Pediatric lymphoma ( )
Schizophrenia ( )
Adult glioblastoma ( )
Glioblastoma multiforme ( )
Hepatocellular carcinoma ( )
UniProt ID
T176A_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Pfam ID
PF04103
Sequence
MGTADSDEMAPEAPQHTHIDVHIHQESALAKLLLTCCSALRPRATQARGSSRLLVASWVM
QIVLGILSAVLGGFFYIRDYTLLVTSGAAIWTGAVAVLAGAAAFIYEKRGGTYWALLRTL
LTLAAFSTAIAALKLWNEDFRYGYSYYNSACRISSSSDWNTPAPTQSPEEVRRLHLCTSF
MDMLKALFRTLQAMLLGVWILLLLASLTPLWLYCWRMFPTKGKRDQKEMLEVSGI

Molecular Interaction Atlas (MIA) of This DOT

18 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Adult lymphoma DISK8IZR Strong Altered Expression [1]
Advanced cancer DISAT1Z9 Strong Biomarker [2]
Carcinoma of esophagus DISS6G4D Strong Biomarker [2]
Carcinoma of liver and intrahepatic biliary tract DIS8WA0W Strong Biomarker [1]
Colorectal carcinoma DIS5PYL0 Strong Posttranslational Modification [3]
Esophageal cancer DISGB2VN Strong Biomarker [2]
Esophageal squamous cell carcinoma DIS5N2GV Strong Biomarker [2]
Liver cancer DISDE4BI Strong Biomarker [1]
Lung carcinoma DISTR26C Strong Altered Expression [1]
Lymphoma DISN6V4S Strong Altered Expression [1]
Metastatic malignant neoplasm DIS86UK6 Strong Posttranslational Modification [3]
Neoplasm DISZKGEW Strong Biomarker [4]
Neoplasm of esophagus DISOLKAQ Strong Biomarker [2]
Pediatric lymphoma DIS51BK2 Strong Altered Expression [1]
Schizophrenia DISSRV2N Strong Biomarker [5]
Adult glioblastoma DISVP4LU Limited Biomarker [4]
Glioblastoma multiforme DISK8246 Limited Biomarker [4]
Hepatocellular carcinoma DIS0J828 Limited Posttranslational Modification [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 Disease(s)
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate decreases the methylation of Transmembrane protein 176A (TMEM176A). [7]
------------------------------------------------------------------------------------
6 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Ciclosporin DMAZJFX Approved Ciclosporin decreases the expression of Transmembrane protein 176A (TMEM176A). [8]
Acetaminophen DMUIE76 Approved Acetaminophen decreases the expression of Transmembrane protein 176A (TMEM176A). [9]
Calcitriol DM8ZVJ7 Approved Calcitriol decreases the expression of Transmembrane protein 176A (TMEM176A). [10]
Triclosan DMZUR4N Approved Triclosan increases the expression of Transmembrane protein 176A (TMEM176A). [11]
Tocopherol DMBIJZ6 Phase 2 Tocopherol increases the expression of Transmembrane protein 176A (TMEM176A). [12]
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene decreases the expression of Transmembrane protein 176A (TMEM176A). [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Drug(s)

References

1 Abnormal accumulation of human transmembrane (TMEM)-176A and 176B proteins is associated with cancer pathology.Acta Histochem. 2012 Nov;114(7):705-12. doi: 10.1016/j.acthis.2011.12.006. Epub 2012 Jan 12.
2 Epigenetic silencing of TMEM176A promotes esophageal squamous cell cancer development.Oncotarget. 2017 Jul 25;8(41):70035-70048. doi: 10.18632/oncotarget.19550. eCollection 2017 Sep 19.
3 Methylation of TMEM176A is an independent prognostic marker and is involved in human colorectal cancer development.Epigenetics. 2017 Jul 3;12(7):575-583. doi: 10.1080/15592294.2017.1341027. Epub 2017 Jul 5.
4 Potential targets of TMEM176A in the growth of glioblastoma cells.Onco Targets Ther. 2018 Nov 2;11:7763-7775. doi: 10.2147/OTT.S179725. eCollection 2018.
5 Exome sequences of multiplex, multigenerational families reveal schizophrenia risk loci with potential implications for neurocognitive performance.Am J Med Genet B Neuropsychiatr Genet. 2017 Dec;174(8):817-827. doi: 10.1002/ajmg.b.32597. Epub 2017 Sep 13.
6 Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma.Clin Epigenetics. 2018 Nov 6;10(1):137. doi: 10.1186/s13148-018-0570-4.
7 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
8 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
9 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
10 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
11 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
12 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.